A multimodal AI biomarker PATH-ORACLE improves prediction of recurrence in stage I lung adenocarcinoma
Extensive validation will be needed to convert PATH-ORACLE from a prognostic biomarker to a predictive biomarker that could be used to prioritize stage IB patients for adjuvant targeted therapy, chemotherapy, or immune checkpoint inhibitor therapy with or without liquid biopsy-based monitoring.